Lilly to sell obesity drugs directly on Hims & Hers site - Reuters

Eli Lilly has entered into a strategic agreement with Hims & Hers to sell obesity drugs directly through the Hims & Hers platform. Following the announcement of this GLP-1 deal, Hims & Hers experienced a rally in its stock price. As a key component of the partnership, Hims & Hers has committed to cease the compounding of GLP-1 medications, specifically mentioning Zepbound, moving forward to align with the direct sales model established with Eli Lilly.